ECSP13013117A - Métodos para tratar la esclerosis múltiple y preservar y/o aumentar el contenido de mielina. - Google Patents

Métodos para tratar la esclerosis múltiple y preservar y/o aumentar el contenido de mielina.

Info

Publication number
ECSP13013117A
ECSP13013117A ECSP13013117A ECSP13013117A EC SP13013117 A ECSP13013117 A EC SP13013117A EC SP13013117 A ECSP13013117 A EC SP13013117A EC SP13013117 A ECSP13013117 A EC SP13013117A
Authority
EC
Ecuador
Prior art keywords
methods
multiple sclerosis
reducing
content
myeline
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Katherine Dawson
Neill Gllmore O
Alfred Sandrock
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47217796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13013117(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of ECSP13013117A publication Critical patent/ECSP13013117A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ECSP13013117 2011-05-26 2013-12-26 Métodos para tratar la esclerosis múltiple y preservar y/o aumentar el contenido de mielina. ECSP13013117A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490572P 2011-05-26 2011-05-26
US201261625624P 2012-04-17 2012-04-17

Publications (1)

Publication Number Publication Date
ECSP13013117A true ECSP13013117A (es) 2014-06-30

Family

ID=47217796

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13013117 ECSP13013117A (es) 2011-05-26 2013-12-26 Métodos para tratar la esclerosis múltiple y preservar y/o aumentar el contenido de mielina.

Country Status (19)

Country Link
US (1) US20140163100A1 (https=)
EP (1) EP2713724A4 (https=)
JP (1) JP2014515373A (https=)
KR (1) KR20140036257A (https=)
CN (1) CN103732062A (https=)
AU (1) AU2012258558A1 (https=)
BR (1) BR112013030169A2 (https=)
CA (1) CA2836480A1 (https=)
CL (1) CL2013003358A1 (https=)
CO (1) CO6811862A2 (https=)
EA (1) EA201391578A1 (https=)
EC (1) ECSP13013117A (https=)
IL (1) IL229448A0 (https=)
MX (1) MX2013013781A (https=)
PE (1) PE20141316A1 (https=)
PH (1) PH12013502443A1 (https=)
SG (1) SG195049A1 (https=)
WO (1) WO2012162669A1 (https=)
ZA (1) ZA201308681B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1663197T1 (sl) 2003-09-09 2008-06-30 Biogen Idec Internat Gmbh Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme
LT2801354T (lt) 2004-10-08 2017-06-26 Forward Pharma A/S Kontroliuojamo atpalaidavimo farmacinės kompozicijos, apimančios fumaro rūgšties esterį
HRP20140640T1 (hr) 2008-08-19 2014-11-21 Xenoport, Inc. Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe
SMT201800098T1 (it) 2011-06-08 2018-03-08 Biogen Ma Inc Processo per la preparazione di dimetilfumarato cristallino e con purezza elevata
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
WO2014031901A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of use for monomethyl fumarate and prodrugs thereof
AR094277A1 (es) 2012-12-21 2015-07-22 Biogen Idec Inc Derivados de fumarato sustituidos con deuterio
BR112015022854A2 (pt) 2013-03-14 2017-07-18 Alkermes Pharma Ireland Ltd pró-farmacos de fumaratos e uso do mesmo no tratamento de várias doenças
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
CN103724198A (zh) * 2013-11-28 2014-04-16 镇江圣安医药有限公司 富马酸二甲酯的新型衍生物及其应用
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
AU2015222880B2 (en) 2014-02-28 2016-11-24 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
AU2014414316B2 (en) * 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
MA40985A (fr) * 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
EP4056179A1 (en) 2014-12-11 2022-09-14 Actelion Pharmaceuticals Ltd Dosing regimen for ponesimod, a selective s1p1 receptor agonist
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
US20080299196A1 (en) * 2005-10-07 2008-12-04 Aditech Pharma Ab Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
SI2139467T1 (sl) * 2007-02-08 2017-01-31 Biogen Ma Inc. Zaščita živčevja pri demielinizacijskih obolenjih
EP2680006A1 (en) * 2007-02-08 2014-01-01 Biogen Idec MA Inc. Treatment for Amyotrophic Lateral Sclerosis
HRP20140640T1 (hr) * 2008-08-19 2014-11-21 Xenoport, Inc. Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe
US20120165404A1 (en) * 2009-04-29 2012-06-28 Biogen Idec Ma Inc. Treatment of neurodegeneration and neuroinflammation

Also Published As

Publication number Publication date
EP2713724A4 (en) 2015-03-11
AU2012258558A1 (en) 2013-05-02
EP2713724A1 (en) 2014-04-09
ZA201308681B (en) 2017-11-29
PE20141316A1 (es) 2014-10-01
CL2013003358A1 (es) 2014-08-01
WO2012162669A1 (en) 2012-11-29
PH12013502443A1 (en) 2019-03-22
CN103732062A (zh) 2014-04-16
MX2013013781A (es) 2014-01-08
SG195049A1 (en) 2013-12-30
EA201391578A1 (ru) 2014-05-30
BR112013030169A2 (pt) 2016-08-09
CO6811862A2 (es) 2013-12-16
KR20140036257A (ko) 2014-03-25
CA2836480A1 (en) 2012-11-29
US20140163100A1 (en) 2014-06-12
IL229448A0 (en) 2014-01-30
JP2014515373A (ja) 2014-06-30

Similar Documents

Publication Publication Date Title
ECSP13013117A (es) Métodos para tratar la esclerosis múltiple y preservar y/o aumentar el contenido de mielina.
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
PH12014501639B1 (en) Pharmaceutical compositions and methods
MX2013003076A (es) Terapeuticos contra cancer de mama.
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
PH12014501032A1 (en) 2-thiopyrimidinones
CO6731092A2 (es) Nueva forma de administración de inhibidor de encefalinasa
MX356025B (es) Uso de glicopirrolato para tratar taquicardia.
GB2525835A (en) Composition comprising a diindolymethane and a retinoid to treat a skin condition
MX357510B (es) Metodos para tratar ataques de gota.
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
MX2014000567A (es) Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
AR080933A1 (es) Tratamiento de esclerosis multiple con masitinib
MX337139B (es) Composicion de miel con l-alanil-l-glutamina.
AU2012307449A8 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
AR084169A1 (es) Combinacion que comprende un derivado de la familia de las combretastatinas y cetuximab
MX2014006990A (es) Tratamiento para diabetes tipo i y tipo ii.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
TN2013000247A1 (en) Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer
Trainor Broome Taxi rides
IN2014KN01142A (https=)
NI201300052A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
UA98076C2 (ru) Применение немодифицированных фуллеренов с60 в качестве противоопухолевых агентов в терапии злокачественных новообразований